Pharmacological Characterization of GB1908, a Selective Galectin-1 Carbohydrate Binding Domain Inhibitor for the Treatment of Cancer
The inhibition of both tumor growth and immune-suppressive cytokines, in cancers in which high Gal-1 is associated with poorer survival outcomes, suggests a potential therapeutic benefit for Gal-1 inhibitors such as GB1908.
Authors
- James A. Roper (ORCID: https://orcid.org/0000-0002-8910-6033)
- Alison C. MacKinnon (ORCID: https://orcid.org/0000-0002-7967-4141)
- Fredrik R. Zetterberg (ORCID: https://orcid.org/0000-0002-7789-8782)
- Ian Holyer
- Kristoffer Peterson (ORCID: https://orcid.org/0000-0002-4683-8293)
- Duncan C. Humphries (ORCID: https://orcid.org/0000-0002-5551-6536)
- Robert J. Slack (ORCID: https://orcid.org/0000-0002-4372-9438)
- Kimberly D. Herman (ORCID: https://orcid.org/0000-0002-8672-0599)
- Anders Kirstein Pedersen
Institutions
- Galecto (Denmark) (DK)
Publication Details
- Journal
- Pharmacology
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1159/000543234
- Citations
- 3
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 2.39